

About the Author

Dr. Sanchez-Montes is a biologist at the Tropical Medicine Center of the Universidad Nacional Autónoma de México, Mexico City, Mexico, in charge of detecting rickettsial agents. His interests are the identification of rickettsial agents, pathogen–host interactions, and epidemiology of zoonotic emerging diseases.

References

1. Guglielmone AA, Robbins RG, Apanaskevich DA, Petney TN, Estrada-Peña A, Horak IG. The hard ticks of the world. Dordrecht (the Netherlands): Springer; 2014. p. 978–94.

2. Guzmán-Cornejo C, Robbins RG, Guglielmone AA, Montiel-Purra G, Pérez TM. The Amblyomma (Acari: Ixodida: Ixodidae) of Mexico: identification keys, distribution and hosts. Zootaxa. 2011;2998:16–38.

3. Bitencourth K, Amorim M, de Oliveira SV, Voioch CM, Guzmán-Cornejo C, Robbins RG, Guglielmone AA, Lamattina D, Tarragona EL, Nava S. Molecular detection of the human pathogen Rickettsia parkeri strain Atlantic Rainforest in Amblyomma ovale ticks in Argentina.Ticks Tick Borne Dis. 2018;9:1261–3. https://doi.org/10.1016/j.ttbdis.2018.05.007

4. Lopes MG, Junior JM, Foster RJ, Harmes BJ, Sanchez E, Martins TF, et al. Ticks and rickettsiae from wildlife in Belize, Central America. Parasit Vectors. 2016;9:62. https://doi.org/10.1186/s13071-016-1348-1

5. Lamattina D, Tarragona EL, Nava S. Molecular detection of the human pathogen Rickettsia parkeri strain Atlantic Rainforest in Amblyomma ovale ticks in Argentina.Ticks Tick Borne Dis. 2018;9:1261–3. https://doi.org/10.1016/j.ttbdis.2018.05.007

6. Sanchez-Montes S, Lopez-Perez AM, Guzmán-Cornejo C, Colunga-Salas P, Becker I, Delgado-de la Mora J, et al. Rickettsia parkeri in Dermacentor parumapertus ticks, Mexico. Emerg Infect Dis. 2018;24:1108–11. https://doi.org/10.3201/eid2406.180058

7. Delgado-de la Mora J, Sanchez-Montes S, Licona-Enrique JD, Delgado-de la Mora D, Paddock CD, Beati L, et al. Rickettsia parkeri and Candidatus Rickettsia andeanae in tick of the Amblyomma maculatum group, Mexico. Emerg Infect Dis. 2019;25:836–8. https://doi.org/10.3201/eid2504.181507

8. Direction General de Epidemiologia. Anuarios de morbidad 1984–2018. 2019 Jun 26 [cited 2019 Sep 18]. https://www.gob.mx/salud/acciones-y-programas/anuarios-de-morbidad-1984-2018

9. Bustamante ME, Varela G. Estudios de fiebre manchada en México: hallazgo del Amblyomma cajennense naturalmente infectado en Veracruz. Rev Inst Salubr Enferm Trop. 1946;7:75–8.

Address for correspondence: Claudia Rangel-Escareño, Instituto Nacional de Medicina Genómica, Laboratorio de Genómica Computacional, Periférico Sur 4809, Arenal Tepepan, 14610, Mexico City, Mexico; email: crangel@inmegen.gob.mx

Rhombencephalitis and Myeloradiculitis Caused by a European Subtype of Tick-Borne Encephalitis Virus

Lorna Neill, Anna M. Checkley, Laura A. Benjamin, M. Trent Herdman, Daniel P. Carter, Steven T. Pullan, Emma Aarons, Katie Griffiths, Bernadette Monaghan, Kushan Karunaratne, Olga Ciccarelli, Jennifer Spillane, David A.J. Moore, Dimitri M. Kullmann

Author affiliations: University College London Hospitals, London, UK (L. Neill, A.M. Checkley, L.A. Benjamin, M.T. Herdman, B. Monaghan, K. Karunaratne, O. Ciccarelli, J. Spillane, D.A.J. Moore, D.M. Kullmann); University College London, London (L.A. Benjamin, O. Ciccarelli, J. Spillane, D.M. Kullmann); Public Health England, Porton Down, UK (M.T. Herdman, D.P. Carter, S.T. Pullan, E. Aarons, K. Griffiths); London School of Hygiene and Tropical Medicine, London (D.A.J. Moore)

DOI: https://doi.org/10.3201/eid2512.191017

We report a case of a previously healthy man returning to the United Kingdom from Lithuania who developed rhombencephalitis and myeloradiculitis due to tick-borne encephalitis. These findings add to sparse data on tick-borne encephalitis virus phylogeny and associated neurologic syndromes and underscore the importance of vaccinating people traveling to endemic regions.

Tick-borne encephalitis virus (TBEV) is an emerging disease caused by a neurotropic flavivirus; its incidence is increasing in north, central, and eastern Europe (1,2). Typical resulting neurologic illnesses include meningitis or meningoencephalitis (3). Cases peak in the summer, when contact between humans and tick vectors is highest, and infection is associated with time spent in meadows and forests (1,2). We report a previously healthy 38-year-old man from the United Kingdom who had unusual neurologic manifestations of TBEV after travel to Lithuania.

The patient, who had received no travel-related vaccinations, traveled to the Kaunas region, where he visited woodlands. He reported having received insect bites on his feet. Seven days after arriving in Lithuania, he developed influenza-like symptoms, which continued after his return to the United Kingdom. Ten days later, he reported neck stiffness, photophobia, slurred speech, tongue deviation to the left, and left leg weakness; the next day, progressive bilateral lower limb weakness in his hips, urinary retention, and constipation developed. At that time, he sought treatment at a hospital.

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 25, No. 12, December 2019 2317
On examination, the patient was febrile (38.0°C) and had a peripheral leukocyte count of $15 \times 10^9$ cells/L and C-reactive protein of 120 mg/L. Cauda equina syndrome was ruled out by using lumbar-sacral magnetic resonance imaging; results of a computed tomography scan of the head were unremarkable. Pleocytosis was identified in the cerebrospinal fluid (CSF), and the patient was empirically treated with ceftriaxone and acyclovir (Appendix Table, https://wwwnc.cdc.gov/EID/article/25/12/19-1017-App.pdf).

Two days after neurologic signs began, the patient became breathless and drowsy. Neurologic examination revealed dysarthria, interrupted saccades, and difficulty with alternating lateral tongue movements. He exhibited a pout reflex and a brisk jaw jerk. Upper limbs had normal tone; power was graded 4+/5 on the Medical Research Council (MRC) scale (https://mrc.ukri.org/research/facilities-and-resources-for-researchers/mrc-scales/mrc-muscle-scale) for shoulder abduction and elbow extension bilaterally but was otherwise normal. The patient had reduced tone in his lower limbs and bilateral proximal muscle weakness affecting hip and knee flexors (MRC grade 1–2/5); distal limb power was less affected (MRC grade 4/5). He was areflexic and had bilateral flexor plantars. Pinprick testing indicated dermatomal sensory loss isolated from L2 to L5 on the left. Forced vital capacity was 800 mL (reference >1,700 mL); therefore, due to respiratory muscle weakness, he was intubated and transferred to a neurology hospital. Repeat CSF testing showed a profile similar to the initial test (Appendix Table). Antituberculosis therapy was added because of the enigmatic etiology.

Magnetic resonance imaging of the brain and spinal cord demonstrated long-segment myelitis with high T2 signal in the central cord extending from C2 through T12; no intracranial lesions or pathological enhancement were seen (Figure). Neurophysiology test results pointed to a preganglionic lesion, with decreased compound muscle action potentials in the L4–S1 myotomes, in the context of a normal motor conduction velocity and sensory nerve action potential. Mild denervation affecting L4–S1 roots did not explain the patient’s degree of weakness. His neurologic syndrome was consistent with rhombencephalitis and myeloradiculitis. High-dose steroid was added to cover the possibility of neuromyelitis optica.

Blood and CSF were screened for inflammatory and infective etiologies (Appendix Table). Serum and urine samples were sent to the Rare and Imported Pathogens Laboratory (Porton Down, UK) for serologic and PCR testing for alphaviruses, flaviviruses, and rickettsial infections. Serum and urine PCR results were positive for TBEV RNA; serum and CSF results were positive for TBEV IgG (Appendix Table). Metagenomic RNA sequencing confirmed TBEV. A total of 129 reads (0.01% of total reads) were identified as TBEV, sufficient to elucidate the full envelope gene sequence at a minimum coverage depth of 5× (when mapped to reference sequence GenBank accession no. KC154190.1). No reads were observed for other pathogens. Phylogenetic analysis of the envelope gene revealed the isolate was most closely related to the European TBEV clade (GenBank accession no. MK992869) (Appendix Figure).

Detection of TBEV RNA from both blood and urine is diagnostic of acute TBEV infection (1). On day 14, antibiotics, antivirals, and steroids were stopped; antituberculosis therapy had been halted earlier. The patient was extubated on day 17 and has slowly recovered. However, he has residual profound proximal left leg weakness and bladder and bowel dysfunction.

Figure. Neurologic manifestations of tick-borne encephalitis in a 38-year-old man from the United Kingdom after travel to Lithuania. A) Magnetic resonance imaging of the brain and spinal cord at onset of neurologic signs, showing possible longitudinal extensive transverse myelitis in the cervical and thoracic cord, with involvement of the central gray matter. B) One month later, increased T2 signal and mild swelling of the central gray matter of the cervical cord have both regressed, with some residual subtle signal changes throughout the spinal cord. Left, axial images; right, sagittal images.
Several subtypes of TBEV cause disease: European, Siberian, and Far Eastern (1). Siberian and Far Eastern have been associated with worse outcomes (1), but the potentially fatal neurologic complications in this patient are consistent with emerging data indicating that the European subtype causes more severe disease than previously thought (4–6). In <10% of cases, TBEV targets the anterior horn of the spinal cord, resulting in flaccid poliomyelitis-like paralysis (3,7), or, rarer still, as in this case, in paralysis of respiratory muscles, requiring artificial ventilation (3,8,9).

Treatment of TBEV is supportive only; vaccination and avoiding mosquito bites are key to disease prevention and control. Although some TBEV-endemic countries have vaccination programs, level of uptake varies (10). Public health experts recommend that travelers undertaking high-exposure activities in endemic countries get vaccinated. This case underscores the importance of vaccination among groups of susceptible people and improved awareness of this emerging disease.

**About the Author**

Dr. Neill is a junior doctor currently working at University College Hospital London. Her research interests include infectious diseases and hematological malignancy.

**References**

1. Taba P, Schmutterd E, Forsberg P, Lutsar I, Mylglan Å, et al. EAN consensus review on prevention, diagnosis and management of tick-borne encephalitis. Eur J Neurol. 2017;24:1214–e61. https://doi.org/10.1111/ejn.13356
2. European Centre for Disease Prevention and Control. Tick-borne encephalitis. In: Annual epidemiological report for 2016. Stockholm: The Centre; 2018.
3. Kaiser R. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994–98: a prospective study of 656 patients. Brain. 1999;122:2067–78. https://doi.org/10.1093/brain/122.11.2067
4. Mansfield KL, Johnson N, Phipps LP, Stephenson JR, Fooks AR, Solomon T. Tick-borne encephalitis virus—a review of an emerging zoonosis. J Gen Virol. 2009;90:1781–94. https://doi.org/10.1099/vir.0.011437-0
5. Kuivanen S, Smura T, Rantanen K, Kämppi L, Kantonen J, Kero M, et al. Fatal tick-borne encephalitis virus infections caused by Siberian and European subtypes, Finland, 2015. Emerg Infect Dis. 2018;24:946–8. https://doi.org/10.3201/eid2405.171986
6. Bender A, Schulte-Altedorneburg G, Walther EU, Pfister HW. Severe tick-borne encephalitis with simultaneous brain stem, bithalamic, and spinal cord involvement documented by MRI. J Neurol Neurosurg Psychiatry. 2005;76:135–7. https://doi.org/10.1093/jnnp/556.5.1169
7. Beer S, Brune N, Kesselring J. Detection of anterior horn lesions by MRI in central European tick-borne encephalomyelitis. J Neurol. 1999;246:1169–71. https://doi.org/10.1007/s004150050537
8. Lenhard T, Ott D, Jakob NJ, Pham M, Bäumer P, Martinez-Torres F, et al. Predictors, neuroimaging characteristics and long-term outcome of severe European tick-borne encephalitis: a prospective cohort study. PLoS ONE. 2016;11:e0154143. https://doi.org/10.1371/journal.pone.0154143
9. Schellinger PD, Schmutterd E, Fiebach JB, Pfausler B, Maier H, Schwab S. Poliomyelitic-like illness in central European encephalitis. Neurology. 2000;55:299–302. https://doi.org/10.1212/WNL.55.2.299
10. Jacob L, Kostev K. Compliance with vaccination against tick-borne encephalitis virus in Germany. Clin Microbiol Infect. 2017;23:460–3. https://doi.org/10.1016/j.cmi.2017.01.012

Address for correspondence: Laura A. Benjamin, UCL Queen Square Institute of Neurology, Stroke Research Centre, Department of Brain Repair and Rehabilitation, Russell Square House, 10-12 Russell Sq, London WC1B 5EH, UK; email: l.benjamin@ucl.ac.uk

---

**Aspergillus felis in Patient with Chronic Granulomatous Disease**

Olivier Paccoud, Romain Guery, Sylvain Poirée, Grégoire Jouvion, Marie Elisabeth Bougnoux, Emilie Catherinot, Olivier Hermine, Olivier Lortholary, Fanny Lanternier

Author affiliations: Hôpital Necker-Enfants Malades, Paris, France (O. Paccoud, R. Guery, S. Poirée, M. E. Bougnoux, O. Hermine, O. Lortholary, F. Lanternier); Institut Pasteur, Paris (G. Jouvion, O. Lortholary, F. Lanternier); Hôpital Foch, Université Versailles-Saint-Quentin-en-Yvelines, Versailles, France (E. Catherinot)

DOI: https://doi.org/10.3201/eid2512.191020

We report a case of *Aspergillus felis* infection in a patient with chronic granulomatous disease who had overlapping features of invasive pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. Identifying the species responsible for aspergillosis by molecular methods can be crucial for directing patient management and selection of appropriate antifungal agents.

---

A 42-year-old man with X-linked chronic granulomatous disease (CGD) sought care at a hospital in Paris, France, for a 2-week history of cough and night sweats. He had been receiving long-term prophylaxis withitraconazole (400 mg/d) and had normal trough levels (1.240 µg/L) 1 month before his hospital visit.

At admission, blood counts showed mild leukocytosis (leukocytes 9.6 × 10⁹ cells/L, reference range 4–10 ×
Rhombencephalitis and Myeloradiculitis Caused by European Subtype of Tick-Borne Encephalitis Virus

Appendix

### Appendix Table. Detailed results of laboratory testing*

| Results                  | Blood                     | Urine                     | CSF                          | CSF                          |
|--------------------------|---------------------------|---------------------------|------------------------------|------------------------------|
| TBE IgM serology         | ND                        | ND                        | ND                           | ND                           |
| TBE IgG serology         | positive [1 in 3200]      | ND                        | ND                           | positive [1 in 100]          |
| TBE RNA PCR              | WCC 15×10⁶ cells/L        | WCC: 308×10⁶ cells/L      | WCC: 430×10⁶ cells/L (60% polym.) |
| Other results            |                           | (90% monon.)              |                              |
|                          |                           | RCC: 12×10⁶ cells/L       |                              |
|                          |                           | Protein: 1.3g/L           |                              |
|                          |                           | Glucose: 2.4mmol/L        |                              |
|                          |                           | OCB: ND                   |                              |
|                          |                           | IgG index: ND             |                              |

**Normal limits:**
- Hb, PLT, U&Es, LFTs, bone profile
- Other results: NMO/MOG, ANA, ANCA, ACE, onconeural antibody, HIV, HTLV-1, syphilis, HHV6, Lyme, rickettsia (spotted fever, typhus), flavivirus (West Nile, sandfly), brucella melitensis

**ACE**, angiotensin converting enzyme; **AFB**, acid fast bacilli; **ANA**, antinuclear acid; **ANCA**, antineutrophil cytoplasmic antibody; **CRAG**, cryptococcal antigen; **CRP**, C-reactive protein; **CSF**, cerebrospinal fluid; **Hb**, haemoglobin; **HHV6**, Human Herpesvirus 6; **HTLV-1**, human T-lymphotrophic virus; **LFTs**, liver function test; **MOG**, myelin oligodendrocyte glycoprotein antibody; **monon.**, mononuclear cells; **ND**, not done; **NMO**, neuromyelitis optica antibody; **OCB**, oligoclonal bands; **OP**, opening pressure; **PLT**, platelet; **polym.**, polymorphonuclear cells; **RCC**, red cell count; **TB**, tuberculosis; **TBE**, Tick-borne encephalitis; **U&Es**, urea and electrolyte; **WCC**, white cell count.

†Days after onset of neurologic syndrome.
Appendix Figure. Phylogenetic tree of tick-borne encephalitis virus in a 38-year-old man from the United Kingdom after travel to Lithuania. Maximum likelihood phylogenetic tree generated using the GTR (generalized time-reversible) model in MEGA7 ([https://www.megasoftware.net](https://www.megasoftware.net)) of representative full
envelope genes of TBEV. The European clade is in red, and the isolate of interest is labeled "MK992869" (red arrow). The green nodes are Siberian, and the blue nodes are Far Eastern subtype. All sequences available for GenBank under the accession numbers shown.